v3.26.1
Business Segments
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Business Segments Business Segments
The Company operates and manages its business in a single reportable segment, which is the management of a portfolio of licensed healthcare assets and development of novel multifunctional biotherapeutics (the “biotherapeutics segment”).
The accounting policies of the biotherapeutics segment are the same as those described in the summary of significant accounting policies.
The Company’s Chief Operating Decision Maker (“CODM”) is the Chair of the Board of Directors and Chief Executive Officer. The CODM assesses performance for the biotherapeutics segment and decides how to allocate resources based on the results of our strategic planning, with segment (loss) income being used to monitor performance against the budgeted costs of that strategy. The measure of segment assets is reported on the balance sheet as total consolidated assets.
Segment profit or loss is measured as net loss presented in the consolidated statements of operations and comprehensive loss. For the purpose of evaluating segment performance and allocating resources, the CODM reviews the Company’s consolidated financial information together with certain operating metrics and evaluates net loss against comparable prior periods and the Company’s annual operating plan. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
In addition to the significant expense categories included within the consolidated statements of loss and comprehensive loss, the following table sets forth disaggregated research and development expenses:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Zanidatamab$2,181 $1,501 $2,805 $2,905 
ZW171(458)3,322 691 5,549 
ZW1913,127 2,764 6,158 4,470 
ZW220(152)327 (55)2,525 
ZW2513,205 2,340 5,112 6,291 
Expense for other preclinical and research programs4,192 6,174 11,456 12,250 
Unallocated research and development expenses:
Salaries and benefits and stock based compensation
10,681 12,034 25,440 24,757 
Other research and development expense4,659 5,987 10,285 11,440 
Total research and development expenses
$27,435 $34,449 $61,892 $70,187